Ultragenyx Pharmaceutical Faces Class Action for Securities Fraud
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy RARE?
Source: Globenewswire
- Class Action Filed: Bronstein, Gewirtz & Grossman, LLC has initiated a class action lawsuit against Ultragenyx Pharmaceutical and certain officers, seeking damages for investors who acquired securities between August 3, 2023, and December 26, 2025, reflecting significant investor dissatisfaction with the company's transparency.
- Allegations of Misrepresentation: The complaint alleges that throughout the class period, defendants made false and/or misleading statements and failed to disclose risks associated with the Phase III Orbit study on Osteogenesis Imperfecta patients, potentially leading investors to misjudge the company's prospects.
- Investor Action Deadline: Affected investors have until April 6, 2026, to request to be appointed as lead plaintiff, indicating the urgency and importance of investor participation in the legal process to share in any potential recovery.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors nationwide, underscoring its expertise in upholding market integrity and investor rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RARE
Wall Street analysts forecast RARE stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 22.750
Low
35.00
Averages
61.65
High
120.00
Current: 22.750
Low
35.00
Averages
61.65
High
120.00
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ultragenyx Pharmaceutical Faces Class Action for Securities Fraud
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Ultragenyx Pharmaceutical and certain officers, alleging violations of federal securities laws affecting all investors who purchased securities between August 3, 2023, and December 26, 2025.
- False Statements Allegation: The complaint alleges that throughout the class period, defendants made false and/or misleading statements and failed to disclose risks associated with the Phase III Orbit study on Osteogenesis Imperfecta patients, leading to investor misconceptions about the study's results.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by April 6, 2026, to share in any potential recovery, highlighting the case's significance and potential impact on investors.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman, LLC has a strong reputation in securities fraud class actions, having recovered hundreds of millions for investors nationwide, emphasizing their expertise in restoring investor capital and ensuring corporate accountability.
See More
Ultragenyx Pharmaceutical Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against Ultragenyx Pharmaceutical on behalf of investors who purchased stock between August 3, 2023, and December 26, 2025, highlighting serious concerns regarding the company's transparency.
- Stock Price Plunge: On December 29, 2025, Ultragenyx shocked the market by revealing that its clinical trials failed to achieve statistical significance, causing its stock price to plummet 42% from $34.19 to $19.72, indicating a significant loss of investor confidence in the company's future.
- False Statement Allegations: The lawsuit alleges that Ultragenyx misled investors by failing to disclose risks associated with its drug's efficacy, which may have resulted in substantial financial losses for investors who relied on the company's optimistic projections.
- Investor Action Recommendation: Affected investors are encouraged to seek lead plaintiff status by April 6, 2026, to represent the class in litigation, underscoring the importance of legal action in safeguarding investor rights.
See More
Ultragenyx Pharmaceutical Class Action Notice
- Lawsuit Background: Kahn Swick & Foti LLC has notified investors in Ultragenyx Pharmaceutical of a class action lawsuit due to alleged securities fraud occurring between August 3, 2023, and December 26, 2025, aimed at recovering losses for affected investors.
- Study Failure Impact: On December 26, 2025, Ultragenyx announced that its Phase 3 studies for setrusumab (UX143) failed to show a statistically significant reduction in annualized fracture rates for Osteogenesis Imperfecta, prompting the company to evaluate and implement significant expense reductions.
- Stock Price Plunge: Following this announcement, Ultragenyx's stock price plummeted approximately 42%, from $34.19 on December 26, 2025, to $19.72 on December 29, 2025, indicating a negative market sentiment regarding the company's future prospects.
- Investor Action Recommendation: Affected investors have until April 6, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff, providing a legal avenue for investors seeking redress.
See More
Ultragenyx to Participate in Three Upcoming Investor Conferences
- Investor Conference Schedule: Ultragenyx Pharmaceutical Inc. will participate in the 46th Annual Cowen Healthcare Conference on March 2, 2026, in Boston, where Chief Medical Officer Eric Crombez will engage in a fireside chat and host one-on-one meetings, aiming to enhance investor interest in the company's novel therapies.
- Global Healthcare Conference: Following this, Ultragenyx will attend the Barclays 28th Annual Global Healthcare Conference in Miami on March 10, 2026, with Eric Crombez again participating in a fireside chat and one-on-one meetings, further showcasing the company's commitment to rare disease treatments.
- Biopharma Conference: Subsequently, Ultragenyx will also take part in the Leerink Partners Global Biopharma Conference on March 11, 2026, where Eric Crombez will continue to engage in a fireside chat and host one-on-one meetings, aiming to attract more investor attention to its product pipeline.
- Webcast Availability: Live and archived webcasts of the fireside chats will be accessible via the company's website, which not only enhances transparency but also provides potential investors with convenient access to information, thereby strengthening the interaction between the company and its investors.
See More
FDA Grants Priority Review for Ultragenyx's DTX401 Gene Therapy Application
- FDA Review Progress: The FDA has granted priority review to Ultragenyx's DTX401 gene therapy application, with a decision expected by August 23, potentially opening new market opportunities for the company in the rare disease treatment sector.
- Therapeutic Potential: DTX401 aims to treat Glycogen Storage Disease Type Ia, and if approved, it would be the first therapy addressing the root cause of the disease, significantly improving patient quality of life and meeting urgent medical needs for patients and families.
- Manufacturing Plans: If approved, Ultragenyx intends to manufacture DTX401 at its new gene therapy facility in Bedford, Massachusetts, which will enhance the company's production capabilities and support future market expansion.
- Market Reaction: Despite RARE stock losing 45% over the past 12 months, investor sentiment on Stocktwits remains in the 'extremely bullish' territory, indicating strong market expectations for the new therapy.
See More
FDA Grants Priority Review for Ultragenyx Gene Therapy DTX401
- FDA Priority Review: The US FDA has granted priority review for Ultragenyx's DTX401 gene therapy (pariglasgene brecaparvovec), with a decision expected by August 23, potentially giving the company a first-mover advantage in rare disease treatment.
- Clinical Data Support: The application is backed by data from 52 patients with up to six years of follow-up, demonstrating significant reductions in the quantity and frequency of daily cornstarch intake, indicating the therapy's potential in treating Glycogen Storage Disease Type Ia.
- Significant Efficacy: Phase 3 trial results showed that patients receiving DTX401 maintained low levels of hypoglycemia and improved euglycemia and fasting tolerance, highlighting the therapy's positive impact on patient quality of life.
- Broad Market Potential: If approved, DTX401 would be the first therapy targeting the root cause of the disease, potentially opening new growth opportunities for Ultragenyx in the biopharmaceutical market and enhancing its competitive position.
See More
Ultragenyx Pharmaceutical Faces Class Action for Securities Fraud
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Ultragenyx Pharmaceutical and certain officers, alleging violations of federal securities laws affecting all investors who purchased securities between August 3, 2023, and December 26, 2025.
- False Statements Allegation: The complaint alleges that throughout the class period, defendants made false and/or misleading statements and failed to disclose risks associated with the Phase III Orbit study on Osteogenesis Imperfecta patients, leading to investor misconceptions about the study's results.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by April 6, 2026, to share in any potential recovery, highlighting the case's significance and potential impact on investors.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman, LLC has a strong reputation in securities fraud class actions, having recovered hundreds of millions for investors nationwide, emphasizing their expertise in restoring investor capital and ensuring corporate accountability.
See More
Ultragenyx Pharmaceutical Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against Ultragenyx Pharmaceutical on behalf of investors who purchased stock between August 3, 2023, and December 26, 2025, highlighting serious concerns regarding the company's transparency.
- Stock Price Plunge: On December 29, 2025, Ultragenyx shocked the market by revealing that its clinical trials failed to achieve statistical significance, causing its stock price to plummet 42% from $34.19 to $19.72, indicating a significant loss of investor confidence in the company's future.
- False Statement Allegations: The lawsuit alleges that Ultragenyx misled investors by failing to disclose risks associated with its drug's efficacy, which may have resulted in substantial financial losses for investors who relied on the company's optimistic projections.
- Investor Action Recommendation: Affected investors are encouraged to seek lead plaintiff status by April 6, 2026, to represent the class in litigation, underscoring the importance of legal action in safeguarding investor rights.
See More
Ultragenyx Pharmaceutical Class Action Notice
- Lawsuit Background: Kahn Swick & Foti LLC has notified investors in Ultragenyx Pharmaceutical of a class action lawsuit due to alleged securities fraud occurring between August 3, 2023, and December 26, 2025, aimed at recovering losses for affected investors.
- Study Failure Impact: On December 26, 2025, Ultragenyx announced that its Phase 3 studies for setrusumab (UX143) failed to show a statistically significant reduction in annualized fracture rates for Osteogenesis Imperfecta, prompting the company to evaluate and implement significant expense reductions.
- Stock Price Plunge: Following this announcement, Ultragenyx's stock price plummeted approximately 42%, from $34.19 on December 26, 2025, to $19.72 on December 29, 2025, indicating a negative market sentiment regarding the company's future prospects.
- Investor Action Recommendation: Affected investors have until April 6, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff, providing a legal avenue for investors seeking redress.
See More
Ultragenyx to Participate in Three Upcoming Investor Conferences
- Investor Conference Schedule: Ultragenyx Pharmaceutical Inc. will participate in the 46th Annual Cowen Healthcare Conference on March 2, 2026, in Boston, where Chief Medical Officer Eric Crombez will engage in a fireside chat and host one-on-one meetings, aiming to enhance investor interest in the company's novel therapies.
- Global Healthcare Conference: Following this, Ultragenyx will attend the Barclays 28th Annual Global Healthcare Conference in Miami on March 10, 2026, with Eric Crombez again participating in a fireside chat and one-on-one meetings, further showcasing the company's commitment to rare disease treatments.
- Biopharma Conference: Subsequently, Ultragenyx will also take part in the Leerink Partners Global Biopharma Conference on March 11, 2026, where Eric Crombez will continue to engage in a fireside chat and host one-on-one meetings, aiming to attract more investor attention to its product pipeline.
- Webcast Availability: Live and archived webcasts of the fireside chats will be accessible via the company's website, which not only enhances transparency but also provides potential investors with convenient access to information, thereby strengthening the interaction between the company and its investors.
See More
FDA Grants Priority Review for Ultragenyx's DTX401 Gene Therapy Application
- FDA Review Progress: The FDA has granted priority review to Ultragenyx's DTX401 gene therapy application, with a decision expected by August 23, potentially opening new market opportunities for the company in the rare disease treatment sector.
- Therapeutic Potential: DTX401 aims to treat Glycogen Storage Disease Type Ia, and if approved, it would be the first therapy addressing the root cause of the disease, significantly improving patient quality of life and meeting urgent medical needs for patients and families.
- Manufacturing Plans: If approved, Ultragenyx intends to manufacture DTX401 at its new gene therapy facility in Bedford, Massachusetts, which will enhance the company's production capabilities and support future market expansion.
- Market Reaction: Despite RARE stock losing 45% over the past 12 months, investor sentiment on Stocktwits remains in the 'extremely bullish' territory, indicating strong market expectations for the new therapy.
See More
FDA Grants Priority Review for Ultragenyx Gene Therapy DTX401
- FDA Priority Review: The US FDA has granted priority review for Ultragenyx's DTX401 gene therapy (pariglasgene brecaparvovec), with a decision expected by August 23, potentially giving the company a first-mover advantage in rare disease treatment.
- Clinical Data Support: The application is backed by data from 52 patients with up to six years of follow-up, demonstrating significant reductions in the quantity and frequency of daily cornstarch intake, indicating the therapy's potential in treating Glycogen Storage Disease Type Ia.
- Significant Efficacy: Phase 3 trial results showed that patients receiving DTX401 maintained low levels of hypoglycemia and improved euglycemia and fasting tolerance, highlighting the therapy's positive impact on patient quality of life.
- Broad Market Potential: If approved, DTX401 would be the first therapy targeting the root cause of the disease, potentially opening new growth opportunities for Ultragenyx in the biopharmaceutical market and enhancing its competitive position.
See More
